| 2026 | Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer
| ESMO OPEN |
| 2025 | Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study | LUNG CANCER |
| 2025 | Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis
| NATURE COMMUNICATIONS |
| 2025 | Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Evolving roles of MET as a therapeutic target in NSCLC and beyond | NATURE REVIEWS CLINICAL ONCOLOGY |
| 2025 | Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
| MOLECULAR CANCER THERAPEUTICS |
| 2025 | The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
| CELL REPORTS MEDICINE |
| 2025 | Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First-Line Chemotherapy
| THORACIC CANCER |
| 2024 | NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
| CANCER DISCOVERY |
| 2024 | Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
| Lung Cancer : targets and therapy |
| 2024 | Foritinib, a type II ROS1 inhibitor for NSCLC | LANCET RESPIRATORY MEDICINE |
| 2024 | Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities | LUNG CANCER |
| 2024 | Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
| CANCER RESEARCH COMMUNICATIONS |
| 2024 | Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey
| Lung Cancer : targets and therapy |
| 2024 | ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?
| Lung Cancer : targets and therapy |
| 2024 | Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
| JOURNAL OF THORACIC ONCOLOGY |
| 2024 | Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC | CLINICAL CANCER RESEARCH |
| 2024 | Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types
| FRONTIERS IN IMMUNOLOGY |
| 2024 | Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC | JOURNAL OF THORACIC ONCOLOGY |
| 2024 | Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report
| JTO Clinical and Research Reports |
| 2024 | Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2024 | Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer | JCO ONCOLOGY PRACTICE |
| 2024 | First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
| 2023 | Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies
| CANCERS |
| 2023 | Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea
| Cancer Treatment and Research Communications |
| 2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
| 2023 | Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
| FRONTIERS IN CHEMISTRY |
| 2022 | The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
| ESMO OPEN |
| 2021 | Cooperative Subtype Switch of Thyroid Hormone Receptor and Nuclear Receptor Corepressor Related Epithelial–Mesenchymal Transition in Papillary Thyroid Cancer
| International Journal of Thyroidology |
| 2021 | Role and Function of O-GlcNAcylation in Cancer
| CANCERS |
| 2021 | Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer
| SCIENTIFIC REPORTS |
| 2021 | Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
| MOLECULES AND CELLS |
| 2021 | Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis
| FRONTIERS IN ONCOLOGY |
| 2020 | Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
| TRIALS |
| 2019 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
| CANCER RESEARCH AND TREATMENT |
http://orcid.org/0000-0001-5608-3157
